SCYX - speculative catalyst playSCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Disclaimer: This is not financial advice.
Upcoming Event: Preclinical Data Release on 04/24/2024
This is a highly speculative investment opportunity.
Recent News Highlights:
SCYNEXIS has been reaffirmed a 'Buy' rating due to strong financials and promising pipeline prospects.
The 'Buy' rating was also reaffirmed based on the success of Ibrexafungerp and a strong partnership with GSK.
Key Price Levels to Watch:
Monitor the resistance levels at $1.70, $1.85, and $2.00. Breaking these levels could indicate a potential upward movement. Consider taking partial profits at these levels to secure gains.
Stop Loss (SL): Set below $1.30 to minimize risk.
Take Profit (TP): Target approximately $2.15.
Additional information can be found in the accompanying chart.
Please trade with caution.
SCYX trade ideas
Biotech highlight: SCYNEXIS (SCYX)Back to back announcements of good news.
This is a relatively new one for me in this space, but the news (in links below) of the NIH grant followed by the FDA approval of an additional indication will make following today's stock-price-action of interest!
www.scynexis.com
www.scynexis.com
(NOTE: NOT ADVICE IN ANYWAY!! JUST FOOD FOR THOUGHT AND DISCUSSION!!)
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANSCYX: Scynexis
2022-02-10 07:36:33
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections, Clearing the Way for Regulatory Submission and Potential Approval of Additional Indication by End of 2022
$SCYX entry PT 6-6.71 Long term PT 18 and higherScynexis to Initiate a Phase 3 Study of Oral Ibrexafungerp as a Step-Down Treatment for Invasive Candidiasis Following Meeting With FDA
SCYNEXIS, Inc., a biotechnology company, delivers therapies for the treatment fungal infections in the United States. It is developing its lead product candidate, ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company develops ibrexafungerp, which has completed Phase II clinical trials for the treatment of vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
SCYNEXIS Announces Positive Results from Interim Analyses of OngSCYX: Scynexis
2021-03-02 07:30:00
SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
SCYX Long. Bullish Descending WedgeSCYX has been consolidating into this bullish wedge for months now. With upcoming catalysts, such as the first FDA approval for their ibrexafungerp antifungal in Q1 2021 and other catalyst announcements potentially in Q4 2020, this looks prime for a large break out over $10.
I will be buying at any price within this wedge with a target >$20 for profit taking.
Technical analysis on SCYXNASDAQ:SCYX
Big picture: it is currently in uptrend channel. Higher highs and lower lows, tightening pattern.
Smaller picture, its underneath EMAs, so that's a bit concerning. But volume looks to be increasing more steadily.
A bit of fundamental analysis, the results from one late stage study should be out this month with positive results so that will be a huge contributing factor. Will probably spring out of this tightening pattern to upper areas in the big picture time frame.
Some chart info:
Moving averages are exponential. Indicator is by LazyBear called 8x MA with configurable lengths
Green: EMA 10
Skinny Red: EMA 20
Thicker Red: EMA 26
Orange: EMA 50
Light Blue: EMA 100
Dark Blue: EMA 200
Skinny Black: EMA 250
Skinny Purple: EMA 300
Bottom indicators are:
RSI (14, CLOSE)
Stoch RSI (3,3,14,25, CLOSE)
Stoch (5,3,3)
ADX and DI (14,20)
Cup and Handle6 month cup and handle here with a weekly breakout with massive volume validating the move, if price manage to close above the newly formed support, here's a great long opportunity, the SL is based on an intraday open price.
the cup and handle suggest a higher target but there’s an important resistance to beat first so that would the TP1.
SCYX - Fallen angel type Long from $1.71 to $2.17 SCYX seems forming a nice little fallen angel formation. We been watching it from a while & it is a speculative long opportunity.
* Trade Criteria *
Date First Found- June 6, 2017
Pattern/Why- Fallen angel pattern
Entry Target Criteria- Break of $1.71
Exit Target Criteria- $2.17
Stop Loss Criteria- $1.54
Please check back for Trade updates. (Note: Trade update is little delayed here.)